A type of ‘supercharged’ immune cell could be mass-produced to fight cancer in cutting-edge immunotherapy treatments, scientists believe.

Imperial College London researchers claim the breakthrough could mark the next generation of CAR-T therapies – backed by the NHS.

The pioneering treatments, which involve reprogramming vital immune cells to kill cancer, costs around £300,000 per patient because they are tailor-made.

Read more


Related Articles


Comments